Mesa Laboratories Stock Price, News & Analysis

Mesa Laboratories (NASDAQ:MLAB) announced a regular quarterly dividend of $0.16 per share, payable on March 15, 2021, to shareholders on record as of February 26, 2021. The company continues to lead in providing critical quality control solutions across various industries, including healthcare and pharmaceuticals. This dividend declaration reflects Mesa Labs' ongoing commitment to rewarding shareholders while maintaining its position as a trusted provider of quality control products and services.

Mesa Laboratories, Inc. (MLAB) reported a 25% increase in revenues for 2Q21, totaling $31,860, compared to the same period last year. However, operating income decreased by 5% to $4,470, and net income fell 16% to $2,679 ($0.51 per diluted share). Non-GAAP adjusted operating income rose by 41% to $9,990. The Sterilization and Disinfection Control division faced challenges, with a 4% decline in revenues. Conversely, the Biopharmaceutical Development division showed strong growth with a 53% sequential revenue increase. The company holds over $240 million in cash, positioning it for future growth opportunities.

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend of $0.16 per share, payable on December 15, 2020. Shareholders on record by November 30, 2020 will benefit from this distribution. Mesa Labs is a leader in quality control solutions across various sectors, including pharmaceuticals and healthcare. The company operates through four divisions, ensuring product integrity and improving safety. However, forward-looking statements mention risks related to demand fluctuations, competition, and COVID-19 impacts on operations.

Mesa Laboratories announced a 14% increase in revenue for Q1 2021, totaling $29,941 compared to the previous year. However, operating income fell 41% to $3,198 and net income dropped 78% to $1,025, equating to $0.22 per diluted share. The results were influenced by unusual items totaling $(364). Organic revenues declined 4% quarter-over-quarter, with the Sterilization division achieving 8% growth. Challenges remain in the Instruments and Biopharmaceutical Development divisions due to COVID-19 impacts, though the company maintains a strong financial position with $230,951 in cash.

Mesa Laboratories has declared a regular quarterly dividend of $0.16 per share, payable on September 15, 2020 to shareholders of record as of August 31, 2020. This payment reflects the company's commitment to returning value to shareholders. Mesa Labs operates in critical sectors like pharmaceuticals and healthcare, focusing on quality control solutions through its four divisions. Investors should note potential risks as the company navigates post-pandemic challenges and competition in the market.

Mesa Laboratories (NASDAQ: MLAB) announced the full exercise of underwriters' option to purchase 90,000 additional shares in its public offering, raising approximately $20.3 million. Combined with the initial offering proceeds, total gross proceeds reach about $155.3 million. The closing for the additional shares was completed on June 16, 2020. Mesa Labs plans to use the net proceeds for general corporate purposes, including potential acquisitions. The offering was conducted under its SEC shelf registration.

Mesa Laboratories, Inc. (NASDAQ: MLAB) announced the pricing of a public offering of 600,000 shares at $225.00 per share, aiming for gross proceeds of approximately $135 million. A 30-day option for underwriters to purchase an additional 90,000 shares is also granted. The offering, anticipated to settle on June 12, 2020, will fund general corporate purposes, including potential acquisitions. The offering is conducted under a shelf registration statement filed with the SEC.

Mesa Laboratories (NASDAQ: MLAB) announced a public offering of $100 million in common stock, with a potential additional $15 million option for underwriters. The offering is subject to market conditions and may not proceed as expected. The company plans to use the net proceeds for general corporate purposes, potentially including acquisitions. Jefferies LLC, J.P. Morgan, and Evercore Group are the joint book-running managers for the offering. Investors should review the prospectus filed with the SEC for detailed information.

Mesa Laboratories, Inc. (NASDAQ:MLAB) reported a 29% revenue increase for Q4 2020, achieving $34,208, and a 14% rise for FY20, totaling $117,687. However, operating income fell 65% to $899 in Q4 and 23% to $7,494 for FY20. Net loss for Q4 was ($1,680), translating to a diluted loss per share of ($0.37). Excluding unusual items, adjusted operating income increased 32% in Q4. The Sterilization and Disinfection Control segment performed well, while Instruments and Continuous Monitoring faced declines due to COVID-19. Management anticipates ongoing challenges from the pandemic impacting sales.